Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporated in 2017 and is headquartered in Burnaby, Canada.